Hormone replacement therapy and cardiovascular risk

被引：6

作者：

Gerhard-Herman M. ^{[1
]}

Hamburg N. ^{[1
]}

Ganz P. ^{[1
]}

机构：

[1] Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115

来源：

Current Cardiology Reports | 2000年 / 2卷 / 4期

关键词：

Estrogen; Postmenopausal Woman; Hormone Replacement Therapy; Raloxifene; Progestin;

D O I：

10.1007/s11886-000-0083-5

中图分类号：

学科分类号：

摘要：

We are reexamining the role of hormone replacement therapy in cardiovascular risk in light of the results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. Prior to this trial, the wealth of evidence in the laboratory and in observational trials suggested that estrogen replacement was associated with significant cardioprotection. The HERS trial was the first randomized trial of this therapy in postmenopausal women with coronary artery disease, and it did not demonstrate a reduction in cardiovascular events in women taking hormone replacement therapy. These findings have made us rethink some of the basic science underlying the cardiovascular effects of hormone replacement therapy. Recent evidence regarding thromboembolic risk, inflammation, and types of hormone replacement therapy is discussed. Copyright © 2000 by Current Science Inc.

引用

页码：288 / 292

页数：4

共 29 条

[1]

Gerhard M., Ganz P., How do we explain the clinical benefits of estrogen? from bedside to bench [editorial

[2]

Comment], Circulation, 92, pp. 5-8, (1995)

[3]

Guetta V., Cannon III R.O., Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women, Circulation, 93, pp. 1928-1937, (1996)

[4]

Hulley S., Grady D., Bush T., Et al., Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comments], JAMA, 280, pp. 605-613, (1998)

[5]

Jick H., Derby L.E., Myers M.W., Et al., Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens [see comments], Lancet, 348, pp. 981-983, (1996)

[6]

Daly E., Vessey M.P., Hawkins M.M., Et al., Risk of venous thromboembolism in users of hormone replacement therapy [see comments], Lancet, 348, pp. 977-980, (1996)

[7]

Grodstein F., Stampfer M.J., Goldhaber S.Z., Et al., Prospective study of exogenous hormones and risk of pulmonary embolism in women [see comments], Lancet, 348, pp. 983-987, (1996)

[8]

Ridker P.M., Hennekens C.H., Rifai N., Et al., Hormone replacement therapy and increased plasma concentration of C-reactive protein, Circulation, 100, pp. 713-716, (1999)

[9]

Cummings S.R., Eckert S., Krueger K.A., Et al., The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [see comments] [published erratum appears, JAMA, 282, (1999)

[10]

JAMA, 281, pp. 2189-2197, (1999)

← 1 2 3 →